Juan Carlos Hernández-Boluda, MD, PhD

Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.

Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.